Pyxis Oncology (PYXS) Stock Forecast, Price Target & Predictions
PYXS Stock Forecast
Pyxis Oncology stock forecast is as follows: an average price target of $9.00 (represents a 147.93% upside from PYXS’s last price of $3.63) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PYXS Price Target
The average price target for Pyxis Oncology (PYXS) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $7.00. This represents a potential 147.93% upside from PYXS's last price of $3.63.
PYXS Analyst Ratings
According to 3 Wall Street analysts, Pyxis Oncology's rating consensus is 'Buy'. The analyst rating breakdown for PYXS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pyxis Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $7.00 | $3.52 | 98.86% | 92.84% |
| Aug 07, 2024 | Bradley Canino | Stifel Nicolaus | $10.00 | $3.13 | 219.49% | 175.48% |
| May 07, 2024 | Farzin Haque | Jefferies | $10.00 | $4.31 | 132.02% | 175.48% |
The latest Pyxis Oncology stock forecast, released on Aug 16, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $7.00, which represents a 98.86% increase from the stock price at the time of the forecast ($3.52), and a 92.84% increase from PYXS last price ($3.63).
Pyxis Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $8.50 | $9.00 |
| Last Closing Price | $3.63 | $3.63 | $3.63 |
| Upside/Downside | -100.00% | 134.16% | 147.93% |
In the current month, the average price target of Pyxis Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pyxis Oncology's last price of $3.63. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 05, 2023 | RBC Capital | - | Outperform | Initialise |
| Apr 25, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Pyxis Oncology's last stock rating was published by H.C. Wainwright on Aug 16, 2024. The company gave PYXS a "Buy" rating, the same as its previous rate.
Pyxis Oncology Financial Forecast
Pyxis Oncology Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $9.33M | $2.83M | - | - | - | - | - | - | $125.00K | $125.00K | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $4.13M | $200.00K | $833.00K | $625.00K |
| High Forecast | $9.33M | $2.83M | - | - | - | - | - | - | $125.00K | $125.00K | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $4.13M | $200.00K | $833.00K | $625.00K |
| Low Forecast | $9.33M | $2.83M | - | - | - | - | - | - | $125.00K | $125.00K | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $4.13M | $200.00K | $833.00K | $625.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Pyxis Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PYXS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Pyxis Oncology EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-17.77M | $-25.35M | $-18.12M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict PYXS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pyxis Oncology's previous annual EBITDA (undefined) of $NaN.
Pyxis Oncology Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-15.60M | $-23.05M | $-15.90M |
| Avg Forecast | $-18.29M | $-19.43M | $-19.24M | $-19.11M | $-19.17M | $-19.30M | $-19.44M | $-19.57M | $-17.24M | $-18.45M | $-18.45M | $-19.36M | $-16.94M | $-19.26M | $-20.47M | $-14.43M | $-28.73M | $-30.67M | $-39.12M |
| High Forecast | $-18.29M | $-19.43M | $-19.24M | $-19.11M | $-19.17M | $-19.30M | $-19.44M | $-19.57M | $-17.24M | $-18.45M | $-18.45M | $-19.36M | $-16.94M | $-17.97M | $-20.47M | $-14.43M | $-20.52M | $-30.67M | $-39.12M |
| Low Forecast | $-18.29M | $-19.43M | $-19.24M | $-19.11M | $-19.17M | $-19.30M | $-19.44M | $-19.57M | $-17.24M | $-18.45M | $-18.45M | $-19.36M | $-16.94M | $-20.54M | $-20.47M | $-14.43M | $-33.42M | $-30.67M | $-39.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.54% | 0.75% | 0.41% |
Pyxis Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PYXS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Pyxis Oncology SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.16M | $10.67M | $6.73M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Pyxis Oncology's average Quarter SG&A projection for Mar 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PYXS last annual SG&A of $6.16M (Dec 23).
Pyxis Oncology EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.27 | $-0.00 | $-0.41 |
| Avg Forecast | $-0.30 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.28 | $-0.30 | $-0.30 | $-0.32 | $-0.28 | $-0.32 | $-0.34 | $-0.24 | $-0.47 | $-0.51 | $-0.65 |
| High Forecast | $-0.30 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.28 | $-0.30 | $-0.30 | $-0.32 | $-0.28 | $-0.30 | $-0.34 | $-0.24 | $-0.34 | $-0.51 | $-0.65 |
| Low Forecast | $-0.30 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.32 | $-0.28 | $-0.30 | $-0.30 | $-0.32 | $-0.28 | $-0.34 | $-0.34 | $-0.24 | $-0.55 | $-0.51 | $-0.65 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.57% | 0.00% | 0.63% |
According to undefined Wall Street analysts, Pyxis Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PYXS previous annual EPS of $NaN (undefined).
Pyxis Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| ELEV | Elevation Oncology | $0.60 | $9.00 | 1400.00% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| PDSB | PDS Bio | $3.12 | $9.00 | 188.46% | Buy |
| INZY | Inozyme Pharma | $5.83 | $14.67 | 151.63% | Buy |
| PYXS | Pyxis Oncology | $3.61 | $9.00 | 149.31% | Buy |
| MREO | Mereo BioPharma Group | $3.95 | $6.75 | 70.89% | Buy |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| ZURA | Zura Bio | $3.88 | $5.00 | 28.87% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.50 | $7.00 | 27.27% | Buy |
| HOOK | HOOKIPA Pharma | $4.78 | $3.00 | -37.24% | Buy |
PYXS Forecast FAQ
Is Pyxis Oncology a good buy?
Yes, according to 3 Wall Street analysts, Pyxis Oncology (PYXS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of PYXS's total ratings.
What is PYXS's price target?
Pyxis Oncology (PYXS) average price target is $9 with a range of $7 to $10, implying a 147.93% from its last price of $3.63. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Pyxis Oncology stock go up soon?
According to Wall Street analysts' prediction for PYXS stock, the company can go up by 147.93% (from the last price of $3.63 to the average price target of $9), up by 175.48% based on the highest stock price target, and up by 92.84% based on the lowest stock price target.
Can Pyxis Oncology stock reach $5?
PYXS's average twelve months analyst stock price target of $9 supports the claim that Pyxis Oncology can reach $5 in the near future.
What are Pyxis Oncology's analysts' financial forecasts?
Pyxis Oncology's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-77.483M (high $-77.483M, low $-77.483M), average SG&A $0 (high $0, low $0), and average EPS is $-1.281 (high $-1.281, low $-1.281). PYXS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $12.16M (high $12.16M, low $12.16M), average EBITDA is $0 (high $0, low $0), average net income is $-76.067M (high $-76.067M, low $-76.067M), average SG&A $0 (high $0, low $0), and average EPS is $-1.257 (high $-1.257, low $-1.257).